title: Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy.
abstract: The administration of cisplatin (CDDP) may influence trace metal concentrations in body fluids. In order to test this hypothesis, the blood concentrations of trace metals were determined during the present study in eight Japanese esophageal and lung cancer patients receiving CDDP-based chemotherapy. The levels of manganese, iron (Fe), cobalt, copper, zinc (Zn), platinum and lead in the plasma were determined by inductively coupled plasma-mass spectrometry. In addition, the serum levels of Fe, transferrin and ferritin were evaluated. The baseline plasma concentration of Fe in patients with esophageal cancer was significantly lower than that in lung cancer patients (P=0.011), although there were no significant differences identified with respect to the plasma levels of other trace metals. The data obtained from six fasting patients without blood transfusion demonstrated that plasma concentrations of Fe increased 3.5-fold soon after CDDP treatment and returned to baseline levels ~10 days after therapy. The excessive Fe levels in the bloodstream induced changes in serum ferritin and transferrin levels. Furthermore, serum Zn levels increased 1.8-fold in the 1-3 days following CDDP treatment, and serum cystatin C levels transiently increased. These findings indicate that serum Fe and Zn levels may be useful to understanding the physiological responses in the early stages of CDDP-based chemotherapy, which may be associated with systemic inflammation and/or tissue distribution of CDDP.
authors.affiliation: Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka 569-1094, Japan; Department of Pharmaceutical Health Care, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo 670-8524, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Department of Pharmaceutical Health Care, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo 670-8524, Japan.
authors.forename: Minoru
authors.initials: M
authors.lastname: Takahashi
authors.affiliation: Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
authors.forename: Riho
authors.initials: R
authors.lastname: Niigata
authors.affiliation: Department of Pharmacy, Kobe University Hospital, Kobe, Hyogo 650-0017, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamashita
authors.affiliation: Department of Pharmacy, Kobe University Hospital, Kobe, Hyogo 650-0017, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Kume
authors.affiliation: Department of Pharmacy, Kobe University Hospital, Kobe, Hyogo 650-0017, Japan.
authors.forename: Midori
authors.initials: M
authors.lastname: Hirai
authors.affiliation: Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yasui
keywords: cisplatin; esophageal cancer; iron; lung cancer; trace metal